
{
  "Company Overview": {
    "Name": "Nephro Care India Ltd",
    "Sector": "Healthcare",
    "Industry": "Healthcare",
    "Business Description": "Incorporated in 2014, Nephro Care India Limited is a comprehensive treatment center located in Kolkata, offering a wide range of clinical and lifestyle solutions.  Services include In-house Dialysis Unit, Outpatient Services in areas of Nephrology, Diabetology, Cardiology, Ophthalmology and Neurology, NABL accredited inhouse Pathology, Inhouse Pharmacy, Advance diagnostic facilities, Renal Nutrition department, Home Care, and Mukti (Lifestyle Support Program), Home Dialysis.",
    "Market Position": "Information not explicitly provided, but peer comparison data suggests a smaller market cap compared to competitors."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 315 Cr.",
    "Current Price": "₹ 191",
    "High/Low": "₹ 379 / ₹ 171",
    "Stock P/E": 107,
    "Book Value": "₹ 32.1",
    "Dividend Yield": "0.00%",
    "ROCE": "60.4%",
    "ROE": "49.1%",
    "Face Value": "₹ 10.0",
    "Debt-to-Equity Ratio": "Information not explicitly provided." 
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sep 2024": {
        "Sales": "17.69 Cr.",
        "Expenses": "14.65 Cr.",
        "Operating Profit": "3.04 Cr.",
        "OPM %": "17.18%",
        "Other Income": "0.47 Cr.",
        "Interest": "0.06 Cr.",
        "Depreciation": "0.45 Cr.",
        "Profit before tax": "3.00 Cr.",
        "Tax %": "27.33%",
        "Net Profit": "2.19 Cr.",
        "EPS in Rs": "1.33"
      },
      "Mar 2024": {
        "Sales": "14.13 Cr.",
        "Expenses": "11.41 Cr.",
        "Operating Profit": "2.72 Cr.",
        "OPM %": "19.25%",
        "Other Income": "0.32 Cr.",
        "Interest": "0.03 Cr.",
        "Depreciation": "0.53 Cr.",
        "Profit before tax": "2.48 Cr.",
        "Tax %": "69.35%",
        "Net Profit": "0.76 Cr.",
        "EPS in Rs": "0.64"
      }
    },
    "Annual Results": {
      "Mar 2020": {
        "Sales": "0.54 Cr.",
        "Net Profit": "-0.01 Cr."
      },
      "Mar 2021": {
        "Sales": "1.82 Cr.",
        "Net Profit": "0.09 Cr."
      },
      "Mar 2022": {
        "Sales": "3.42 Cr.",
        "Net Profit": "-0.01 Cr."
      },
      "Mar 2023": {
        "Sales": "17.09 Cr.",
        "Net Profit": "2.37 Cr."
      },
      "Mar 2024": {
        "Sales": "27.23 Cr.",
        "Net Profit": "4.41 Cr."
      },
      "TTM": {
        "Sales": "31.82 Cr.",
        "Net Profit": "2.95 Cr."
      }
    },
    "Balance Sheet Highlights": {
      "Mar 2020": {
        "Equity Capital": "0.01 Cr.",
        "Reserves": "0.07 Cr.",
        "Borrowings": "0.40 Cr.",
        "Other Liabilities": "0.30 Cr.",
        "Total Liabilities": "0.78 Cr.",
        "Fixed Assets": "0.45 Cr.",
        "CWIP": "0.00 Cr.",
        "Investments": "0.24 Cr.",
        "Other Assets": "0.09 Cr.",
        "Total Assets": "0.78 Cr."
      },
      "Mar 2024": {
        "Equity Capital": "11.90 Cr.",
        "Reserves": "3.12 Cr.",
        "Borrowings": "0.00 Cr.",
        "Other Liabilities": "5.94 Cr.",
        "Total Liabilities": "20.96 Cr.",
        "Fixed Assets": "4.74 Cr.",
        "CWIP": "0.86 Cr.",
        "Investments": "6.51 Cr.",
        "Other Assets": "8.85 Cr.",
        "Total Assets": "20.96 Cr."
      },
      "Sep 2024": {
        "Equity Capital": "16.49 Cr.",
        "Reserves": "36.46 Cr.",
        "Borrowings": "0.00 Cr.",
        "Other Liabilities": "14.21 Cr.",
        "Total Liabilities": "67.16 Cr.",
        "Fixed Assets": "5.70 Cr.",
        "CWIP": "17.78 Cr.",
        "Investments": "25.03 Cr.",
        "Other Assets": "18.65 Cr.",
        "Total Assets": "67.16 Cr."
      }
    },
    "Cash Flow Summaries": {
      "Mar 2020": {
        "Cash from Operating Activity": "0.23 Cr.",
        "Cash from Investing Activity": "-0.06 Cr.",
        "Cash from Financing Activity": "0.28 Cr.",
        "Net Cash Flow": "0.44 Cr."
      },
      "Mar 2024": {
        "Cash from Operating Activity": "0.91 Cr.",
        "Cash from Investing Activity": "-7.54 Cr.",
        "Cash from Financing Activity": "5.60 Cr.",
        "Net Cash Flow": "-1.03 Cr."
      }
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth": {
        "3 Years": "146%",
        "TTM": "59%"
      },
      "Compounded Profit Growth": {
        "3 Years": "263%",
        "TTM": "82%"
      },
      "Stock Price CAGR": {
        "1 Year": "Information not available"
      }
    },
    "Liquidity Ratios": {
      "Information not explicitly provided.": null
    },
    "Profitability Ratios": {
      "ROCE %": {
        "Mar 2020": "25.21%",
        "Mar 2024": "60.41%"
      },
      "ROE": {
        "3 Years": "60%",
        "Last Year": "49%"
      }
    },
    "Valuation Ratios": {
      "P/E": 107,
      "Price to Book": "Information not explicitly provided in a ratio format."
    },
    "Turnover Ratios": {
      "Debtor Days": {
        "Mar 2024": "2.01"
      },
      "Inventory Days": {
        "Mar 2024": "14.07"
      },
      "Days Payable": {
        "Mar 2024": "75.17"
      },
      "Cash Conversion Cycle": {
        "Mar 2024": "-59.09"
      },
      "Working Capital Days": {
        "Mar 2024": "-36.86"
      }
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Max Healthcare", "CMP": 1165.20, "P/E": 106.97, "Mar Cap": 113272.83, "Div Yld": 0.13, "NP Qtr": 281.81, "Qtr Profit Var": 1.85, "Sales Qtr": 1707.46, "Qtr Sales Var": 25.26, "ROCE": 16.00},
      {"Name": "Apollo Hospitals", "CMP": 7251.70, "P/E": 88.13, "Mar Cap": 104268.32, "Div Yld": 0.22, "NP Qtr": 395.70, "Qtr Profit Var": 63.46, "Sales Qtr": 5589.30, "Qtr Sales Var": 15.32, "ROCE": 15.11},
      {"Name": "Fortis Health.", "CMP": 677.85, "P/E": 74.39, "Mar Cap": 51174.84, "Div Yld": 0.15, "NP Qtr": 193.08, "Qtr Profit Var": 26.85, "Sales Qtr": 1988.39, "Qtr Sales Var": 12.34, "ROCE": 10.34},
      {"Name": "Global Health", "CMP": 1098.60, "P/E": 60.47, "Mar Cap": 29507.01, "Div Yld": 0.00, "NP Qtr": 130.81, "Qtr Profit Var": 4.51, "Sales Qtr": 956.56, "Qtr Sales Var": 13.34, "ROCE": 19.32},
      {"Name": "Narayana Hrudaya", "CMP": 1288.10, "P/E": 33.80, "Mar Cap": 26323.72, "Div Yld": 0.31, "NP Qtr": 198.80, "Qtr Profit Var": -12.34, "Sales Qtr": 1400.01, "Qtr Sales Var": 7.26, "ROCE": 26.54},
      {"Name": "Poly Medicure", "CMP": 2595.75, "P/E": 89.20, "Mar Cap": 26301.62, "Div Yld": 0.12, "NP Qtr": 87.45, "Qtr Profit Var": 40.62, "Sales Qtr": 420.02, "Qtr Sales Var": 24.53, "ROCE": 23.62},
      {"Name": "Dr Lal Pathlabs", "CMP": 2946.25, "P/E": 61.35, "Mar Cap": 24625.42, "Div Yld": 0.81, "NP Qtr": 130.80, "Qtr Profit Var": 18.21, "Sales Qtr": 660.20, "Qtr Sales Var": 9.80, "ROCE": 25.17}
    ],
    "Median": {
      "CMP": 572.25,
      "P/E": 60.91,
      "Mar Cap": 4461.75,
      "Div Yld": 0.13,
      "NP Qtr": 21.97,
      "Qtr Profit Var": 25.87,
      "Sales Qtr": 182.95,
      "Qtr Sales Var": 14.06,
      "ROCE": 18.72
    }
  },
  "Other Insights": {
    "Pros": [
      "Company has reduced debt.",
      "Company is almost debt free.",
      "Company has a good return on equity (ROE) track record: 3 Years ROE 59.5%"
    ],
    "Cons": [
      "Though the company is reporting repeated profits, it is not paying out dividend",
      "Promoter holding has decreased over last quarter: -23.6%"
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis." ,
    "Shareholding Pattern": {
      "Sep 2024": {
        "Promoters": "61.38%",
        "FIIs": "3.92%",
        "DIIs": "4.82%",
        "Public": "29.87%",
        "No. of Shareholders": 852
      }
    },
    "Notes on Shareholding Data": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
  },
  "Documents": {
    "Announcements": [
      {"Title": "Reply to Clarification- Financial results", "Date": "20 December 2024"},
      {"Title": "Clarification - Financial Results", "Date": "13 December 2024"},
      {"Title": "Financial Result Updates", "Date": "8 November 2024"},
      {"Title": "Outcome of Board Meeting", "Date": "8 November 2024"},
      {"Title": "Board Meeting Intimation", "Date": "30 October 2024"}
    ],
    "Annual Reports": "Financial Year 2024 from nse"
  }
}
